Key Highlights

  • McKesson's diluted EPS for the quarter ended September 30, 2026 came to USD 10.44, a step up from USD 8.92 a year earlier, an increase near 17% (calculated).
  • Top line expanded by 8% to USD 110,957 million, while Gross Profit reached USD 3,956 million, a 12% gain, and Operating Income closed at USD 1,604 million, up from USD 1,407 million a year before.
  • Attributable Net Income moved up to USD 1,218 million from USD 1,110 million, and the diluted share base dropped from 124.4 million to 116.7 million.
  • Across the first six months, Shareholder payouts totaled USD 3.6 billion, and the quarterly Dividend rose to USD 0.94 per share, versus USD 0.82 previously.

Volume Growth and Fewer Shares Support Second-Quarter Earnings

The fiscal second quarter 2027 filing from McKesson (NYSE:MCK) landed on November 4, 2026 and covers the period ended September 30. Sales climbed to roughly USD 111 billion, with gross Margin improving by 14 basis points to 3.57%. Spending on operations rose 10% to USD 2,352 million, and that total absorbed USD 85 million of restructuring and Impairment costs versus USD 63 million the year earlier. Borrowing expense increased to USD 105 million from USD 74 million, and the tax bill came to USD 266 million. Within North American Pharmaceutical, profit improved thanks to greater distribution throughput plus part of an antitrust settlement, while Oncology and Multispecialty pulled ahead on specialty drug demand.

Medical-Surgical Separation, Apollo Capital and New Borrowing

Management intends to spin off its Medical-Surgical Solutions operation as a standalone entity. Back in June, investors affiliated with Apollo bought convertible preferred stock in that unit for roughly USD 1.25 billion, a stake near 13%. Separation expenses booked in the quarter reached USD 42 million inside the segment and USD 4 million at the corporate level. The unit's subsidiaries also secured term Debt and a revolving line that together produced USD 3.2 billion, while the parent closed a USD 5.0 billion unsecured Facility due 2031. Noncontrolling holders received USD 78 million, which includes a USD 17 million Redemption value change. Other income reached USD 63 million, lifting pre-tax income to USD 1,562 million from USD 1,395 million.

Six-Month Buybacks, a Higher Dividend and Policy Exposure

Across the first half of the fiscal year, repurchases took USD 3.4 billion and dividends USD 198 million, and roughly USD 4.3 billion of approved buyback capacity remained after the board added USD 5.0 billion on April 29, 2026. Diluted EPS for six months reached USD 15.53, compared with USD 15.16, with the advance held back by USD 391 million of redemption value changes recorded in the first quarter. Regulatory exposure is flagged, notably drug pricing rules and the federal 340B initiative. The extract includes no numeric forward guidance, so only reported results are cited. Officials say they find the timing and scope of future policy shifts hard to forecast.

Where Things Stand

Volume and a lower share count did most of the work. McKesson (NYSE:MCK) lifted sales 8% and operating income roughly 14% (calculated), and repurchases trimmed diluted shares about 6% (calculated), so net income up near 10% (calculated) became EPS up near 17% (calculated). Higher borrowing costs and separation spending are the drags. Track the separation timeline, how the new debt is deployed, drug pricing rules, and how much of the USD 4.3 billion buyback capacity gets used.